$125.59▼ 0.28 (0.22%)
Real-time prices · US MarketsHigh-quality business with 43% return on equity and 31% profit margins.
Quality
9.6
Health
7.6
Growth
7.9
Valuation
7.7
Sentiment
7.8
Analyst Target
$157.57
▲ +25.5% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
17.1×
price-to-earnings
Forward P/E
13.0×
next 12 months est.
Market Cap
$155.9B
market capitalization
Div Yield
2.61%
dividend yield
Profit Margin
31.0%
net profit margin
Gross Margin
79.4%
revenue minus COGS
ROE
43.4%
return on equity
Beta
0.33
vs S&P 500
52-Week Range
$104 — $157
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Gilead Sciences, Inc. right now?
Gilead Sciences, Inc.'s Q·Score is 8.2/10 (Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. High-quality business with 43% return on equity and 31% profit margins. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for GILD?
The consensus price target for GILD is $157.57, based on ratings from 28 Wall Street analysts. This is 25.5% above the current price of $125.59. Price targets are forward-looking estimates and not guarantees of future performance.
Is GILD overvalued or undervalued?
Gilead Sciences, Inc. (GILD) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 13.0×. The consensus analyst price target of $157.57 is 25% above the current price.
When does Gilead Sciences, Inc. report its next earnings?
Gilead Sciences, Inc.'s next earnings report is expected on approximately August 6, 2026.
What is Gilead Sciences, Inc.'s profit margin?
Gilead Sciences, Inc. has a net profit margin of 31.0%, which is considered high and reflects strong pricing power. Its gross margin stands at 79.4%, indicating a high-margin business model.
What is GILD's dividend yield?
Gilead Sciences, Inc. currently offers a dividend yield of 2.61%, which is above the typical market average dividend yield. Dividend yields can change based on price movements and company payout decisions.
Is Gilead Sciences, Inc.'s revenue growing?
Gilead Sciences, Inc. is reporting modest revenue growth of 4.4%. Earnings are also growing at 54.8%, indicating improving profitability.
How much debt does Gilead Sciences, Inc. have?
Gilead Sciences, Inc. has a debt-to-equity ratio of 0.95×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.97×, indicating comfortable short-term liquidity.
Compare GILD with any stock